Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Use of the dye-guided sentinel lymph node biopsy method alone for breast cancer metastasis to avoid unnecessary axillary lymph node dissection</title><author><name sortKey="Takamaru, Tomoko" sort="Takamaru, Tomoko" uniqKey="Takamaru T" first="Tomoko" last="Takamaru">Tomoko Takamaru</name><affiliation><nlm:aff id="af1-etm-07-02-0456">First Department of Surgery, Sapporo Medical University, Sapporo, Hokkaido 060-8543, Japan</nlm:aff></affiliation></author><author><name sortKey="Kutomi, Goro" sort="Kutomi, Goro" uniqKey="Kutomi G" first="Goro" last="Kutomi">Goro Kutomi</name><affiliation><nlm:aff id="af1-etm-07-02-0456">First Department of Surgery, Sapporo Medical University, Sapporo, Hokkaido 060-8543, Japan</nlm:aff></affiliation></author><author><name sortKey="Satomi, Fukino" sort="Satomi, Fukino" uniqKey="Satomi F" first="Fukino" last="Satomi">Fukino Satomi</name><affiliation><nlm:aff id="af1-etm-07-02-0456">First Department of Surgery, Sapporo Medical University, Sapporo, Hokkaido 060-8543, Japan</nlm:aff></affiliation></author><author><name sortKey="Shima, Hiroaki" sort="Shima, Hiroaki" uniqKey="Shima H" first="Hiroaki" last="Shima">Hiroaki Shima</name><affiliation><nlm:aff id="af1-etm-07-02-0456">First Department of Surgery, Sapporo Medical University, Sapporo, Hokkaido 060-8543, Japan</nlm:aff></affiliation></author><author><name sortKey="Ohno, Keisuke" sort="Ohno, Keisuke" uniqKey="Ohno K" first="Keisuke" last="Ohno">Keisuke Ohno</name><affiliation><nlm:aff id="af1-etm-07-02-0456">First Department of Surgery, Sapporo Medical University, Sapporo, Hokkaido 060-8543, Japan</nlm:aff></affiliation></author><author><name sortKey="Kameshima, Hidekazu" sort="Kameshima, Hidekazu" uniqKey="Kameshima H" first="Hidekazu" last="Kameshima">Hidekazu Kameshima</name><affiliation><nlm:aff id="af1-etm-07-02-0456">First Department of Surgery, Sapporo Medical University, Sapporo, Hokkaido 060-8543, Japan</nlm:aff></affiliation></author><author><name sortKey="Suzuki, Yasuyo" sort="Suzuki, Yasuyo" uniqKey="Suzuki Y" first="Yasuyo" last="Suzuki">Yasuyo Suzuki</name><affiliation><nlm:aff id="af1-etm-07-02-0456">First Department of Surgery, Sapporo Medical University, Sapporo, Hokkaido 060-8543, Japan</nlm:aff></affiliation></author><author><name sortKey="Ohmura, Tousei" sort="Ohmura, Tousei" uniqKey="Ohmura T" first="Tousei" last="Ohmura">Tousei Ohmura</name><affiliation><nlm:aff id="af1-etm-07-02-0456">First Department of Surgery, Sapporo Medical University, Sapporo, Hokkaido 060-8543, Japan</nlm:aff></affiliation></author><author><name sortKey="Takamaru, Hiroyuki" sort="Takamaru, Hiroyuki" uniqKey="Takamaru H" first="Hiroyuki" last="Takamaru">Hiroyuki Takamaru</name><affiliation><nlm:aff id="af2-etm-07-02-0456">First Department of Internal Medicine, Sapporo Medical University, Sapporo, Hokkaido 060-8543, Japan</nlm:aff></affiliation></author><author><name sortKey="Nojima, Masanori" sort="Nojima, Masanori" uniqKey="Nojima M" first="Masanori" last="Nojima">Masanori Nojima</name><affiliation><nlm:aff id="af3-etm-07-02-0456">Department of Public Health, Sapporo Medical University, Sapporo, Hokkaido 060-8556, Japan</nlm:aff></affiliation></author><author><name sortKey="Mori, Mitsuru" sort="Mori, Mitsuru" uniqKey="Mori M" first="Mitsuru" last="Mori">Mitsuru Mori</name><affiliation><nlm:aff id="af3-etm-07-02-0456">Department of Public Health, Sapporo Medical University, Sapporo, Hokkaido 060-8556, Japan</nlm:aff></affiliation></author><author><name sortKey="Hirata, Koichi" sort="Hirata, Koichi" uniqKey="Hirata K" first="Koichi" last="Hirata">Koichi Hirata</name><affiliation><nlm:aff id="af1-etm-07-02-0456">First Department of Surgery, Sapporo Medical University, Sapporo, Hokkaido 060-8543, Japan</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">24396425</idno><idno type="pmc">3881064</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3881064</idno><idno type="RBID">PMC:3881064</idno><idno type="doi">10.3892/etm.2013.1445</idno><date when="2013">2013</date><idno type="wicri:Area/Pmc/Corpus">003E38</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">003E38</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Use of the dye-guided sentinel lymph node biopsy method alone for breast cancer metastasis to avoid unnecessary axillary lymph node dissection</title><author><name sortKey="Takamaru, Tomoko" sort="Takamaru, Tomoko" uniqKey="Takamaru T" first="Tomoko" last="Takamaru">Tomoko Takamaru</name><affiliation><nlm:aff id="af1-etm-07-02-0456">First Department of Surgery, Sapporo Medical University, Sapporo, Hokkaido 060-8543, Japan</nlm:aff></affiliation></author><author><name sortKey="Kutomi, Goro" sort="Kutomi, Goro" uniqKey="Kutomi G" first="Goro" last="Kutomi">Goro Kutomi</name><affiliation><nlm:aff id="af1-etm-07-02-0456">First Department of Surgery, Sapporo Medical University, Sapporo, Hokkaido 060-8543, Japan</nlm:aff></affiliation></author><author><name sortKey="Satomi, Fukino" sort="Satomi, Fukino" uniqKey="Satomi F" first="Fukino" last="Satomi">Fukino Satomi</name><affiliation><nlm:aff id="af1-etm-07-02-0456">First Department of Surgery, Sapporo Medical University, Sapporo, Hokkaido 060-8543, Japan</nlm:aff></affiliation></author><author><name sortKey="Shima, Hiroaki" sort="Shima, Hiroaki" uniqKey="Shima H" first="Hiroaki" last="Shima">Hiroaki Shima</name><affiliation><nlm:aff id="af1-etm-07-02-0456">First Department of Surgery, Sapporo Medical University, Sapporo, Hokkaido 060-8543, Japan</nlm:aff></affiliation></author><author><name sortKey="Ohno, Keisuke" sort="Ohno, Keisuke" uniqKey="Ohno K" first="Keisuke" last="Ohno">Keisuke Ohno</name><affiliation><nlm:aff id="af1-etm-07-02-0456">First Department of Surgery, Sapporo Medical University, Sapporo, Hokkaido 060-8543, Japan</nlm:aff></affiliation></author><author><name sortKey="Kameshima, Hidekazu" sort="Kameshima, Hidekazu" uniqKey="Kameshima H" first="Hidekazu" last="Kameshima">Hidekazu Kameshima</name><affiliation><nlm:aff id="af1-etm-07-02-0456">First Department of Surgery, Sapporo Medical University, Sapporo, Hokkaido 060-8543, Japan</nlm:aff></affiliation></author><author><name sortKey="Suzuki, Yasuyo" sort="Suzuki, Yasuyo" uniqKey="Suzuki Y" first="Yasuyo" last="Suzuki">Yasuyo Suzuki</name><affiliation><nlm:aff id="af1-etm-07-02-0456">First Department of Surgery, Sapporo Medical University, Sapporo, Hokkaido 060-8543, Japan</nlm:aff></affiliation></author><author><name sortKey="Ohmura, Tousei" sort="Ohmura, Tousei" uniqKey="Ohmura T" first="Tousei" last="Ohmura">Tousei Ohmura</name><affiliation><nlm:aff id="af1-etm-07-02-0456">First Department of Surgery, Sapporo Medical University, Sapporo, Hokkaido 060-8543, Japan</nlm:aff></affiliation></author><author><name sortKey="Takamaru, Hiroyuki" sort="Takamaru, Hiroyuki" uniqKey="Takamaru H" first="Hiroyuki" last="Takamaru">Hiroyuki Takamaru</name><affiliation><nlm:aff id="af2-etm-07-02-0456">First Department of Internal Medicine, Sapporo Medical University, Sapporo, Hokkaido 060-8543, Japan</nlm:aff></affiliation></author><author><name sortKey="Nojima, Masanori" sort="Nojima, Masanori" uniqKey="Nojima M" first="Masanori" last="Nojima">Masanori Nojima</name><affiliation><nlm:aff id="af3-etm-07-02-0456">Department of Public Health, Sapporo Medical University, Sapporo, Hokkaido 060-8556, Japan</nlm:aff></affiliation></author><author><name sortKey="Mori, Mitsuru" sort="Mori, Mitsuru" uniqKey="Mori M" first="Mitsuru" last="Mori">Mitsuru Mori</name><affiliation><nlm:aff id="af3-etm-07-02-0456">Department of Public Health, Sapporo Medical University, Sapporo, Hokkaido 060-8556, Japan</nlm:aff></affiliation></author><author><name sortKey="Hirata, Koichi" sort="Hirata, Koichi" uniqKey="Hirata K" first="Koichi" last="Hirata">Koichi Hirata</name><affiliation><nlm:aff id="af1-etm-07-02-0456">First Department of Surgery, Sapporo Medical University, Sapporo, Hokkaido 060-8543, Japan</nlm:aff></affiliation></author></analytic><series><title level="j">Experimental and Therapeutic Medicine</title><idno type="ISSN">1792-0981</idno><idno type="eISSN">1792-1015</idno><imprint><date when="2013">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>For sentinel lymph node biopsy (SLNB), a combination of dye-guided and γ-probe-guided methods is the most commonly used technique. However, the number of institutes in which the γ-probe-guided method is able to be performed is limited, since special equipment is required for the method. In this study, SLNB with the dye-guided method alone was evaluated, and the clinicopathological characteristics were analyzed to identify any factors that were predictive of whether the follow-up axillary lymph node dissection (ALND) was able to be omitted. A total of 374 patients who underwent SLNB between 1999 and 2009 were studied. The SLN identification rate was analyzed, in addition to the false-positive and false-negative rates and the correlation between the clinicopathological characteristics and axillary lymph node metastases. The SLN was identified in 96.8% of cases, and, out of the patients who had SLN metastasis, 63.0% did not exhibit metastasis elsewhere. The sensitivity was 96.4% and the specificity was 100%. The false-negative rate was 3.6%. Univariate analyses revealed significant differences in the lymph vessel invasion (ly) status, nuclear grade (NG), maximum tumor size and the percentage of the area occupied by the tumor cells in the SLN (SLN occupation ratio) between the patients with and without non-SLN metastasis, indicating that these factors may be predictive of axillary lymph node metastasis. Multivariate analysis revealed that ly status was an independent risk factor for non-SLN metastasis. In conclusion, SLN with the dye-guided method alone provided a high detection rate. The study identified a predictive factor for axillary lymph node metastasis that may improve the patients’ quality of life.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Senofsky, Gm" uniqKey="Senofsky G">GM Senofsky</name></author><author><name sortKey="Moffat, Fl" uniqKey="Moffat F">FL Moffat</name></author><author><name sortKey="Davis, K" uniqKey="Davis K">K Davis</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fentiman, Is" uniqKey="Fentiman I">IS Fentiman</name></author><author><name sortKey="Mansel, Re" uniqKey="Mansel R">RE Mansel</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Noguchi, M" uniqKey="Noguchi M">M Noguchi</name></author><author><name sortKey="Miwa, K" uniqKey="Miwa K">K Miwa</name></author><author><name sortKey="Michigishi, T" uniqKey="Michigishi T">T Michigishi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kissin, Mw" uniqKey="Kissin M">MW Kissin</name></author><author><name sortKey="Querci Della Rovere, G" uniqKey="Querci Della Rovere G">G Querci della Rovere</name></author><author><name sortKey="Easton, D" uniqKey="Easton D">D Easton</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cox, C" uniqKey="Cox C">C Cox</name></author><author><name sortKey="White, L" uniqKey="White L">L White</name></author><author><name sortKey="Allred, N" uniqKey="Allred N">N Allred</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kuijt, Gp" uniqKey="Kuijt G">GP Kuijt</name></author><author><name sortKey="Van De Poll Franse, Lv" uniqKey="Van De Poll Franse L">LV van de Poll-Franse</name></author><author><name sortKey="Voogd, Ac" uniqKey="Voogd A">AC Voogd</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Langer, I" uniqKey="Langer I">I Langer</name></author><author><name sortKey="Guller, U" uniqKey="Guller U">U Guller</name></author><author><name sortKey="Hsu Schmitz, Sf" uniqKey="Hsu Schmitz S">SF Hsu-Schmitz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Van Der Ploeg, Im" uniqKey="Van Der Ploeg I">IM van der Ploeg</name></author><author><name sortKey="Nieweg, Oe" uniqKey="Nieweg O">OE Nieweg</name></author><author><name sortKey="Van Rijk, Mc" uniqKey="Van Rijk M">MC van Rijk</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lucci, A" uniqKey="Lucci A">A Lucci</name></author><author><name sortKey="Mccall, Lm" uniqKey="Mccall L">LM McCall</name></author><author><name sortKey="Beitsch, Pd" uniqKey="Beitsch P">PD Beitsch</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Celebioglu, F" uniqKey="Celebioglu F">F Celebioglu</name></author><author><name sortKey="Perbeck, L" uniqKey="Perbeck L">L Perbeck</name></author><author><name sortKey="Frisell, J" uniqKey="Frisell J">J Frisell</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cox, Ce" uniqKey="Cox C">CE Cox</name></author><author><name sortKey="Bass, Ss" uniqKey="Bass S">SS Bass</name></author><author><name sortKey="Mccann, Cr" uniqKey="Mccann C">CR McCann</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kim, T" uniqKey="Kim T">T Kim</name></author><author><name sortKey="Giuliano, Ae" uniqKey="Giuliano A">AE Giuliano</name></author><author><name sortKey="Lyman, Gh" uniqKey="Lyman G">GH Lyman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Morrow, M" uniqKey="Morrow M">M Morrow</name></author><author><name sortKey="Rademaker, Aw" uniqKey="Rademaker A">AW Rademaker</name></author><author><name sortKey="Bethke, Kp" uniqKey="Bethke K">KP Bethke</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Exp Ther Med</journal-id><journal-id journal-id-type="iso-abbrev">Exp Ther Med</journal-id><journal-id journal-id-type="publisher-id">ETM</journal-id><journal-title-group><journal-title>Experimental and Therapeutic Medicine</journal-title></journal-title-group><issn pub-type="ppub">1792-0981</issn><issn pub-type="epub">1792-1015</issn><publisher><publisher-name>D.A. Spandidos</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24396425</article-id><article-id pub-id-type="pmc">3881064</article-id><article-id pub-id-type="doi">10.3892/etm.2013.1445</article-id><article-id pub-id-type="publisher-id">etm-07-02-0456</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Use of the dye-guided sentinel lymph node biopsy method alone for breast cancer metastasis to avoid unnecessary axillary lymph node dissection</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>TAKAMARU</surname><given-names>TOMOKO</given-names></name><xref ref-type="aff" rid="af1-etm-07-02-0456">1</xref></contrib><contrib contrib-type="author"><name><surname>KUTOMI</surname><given-names>GORO</given-names></name><xref ref-type="aff" rid="af1-etm-07-02-0456">1</xref></contrib><contrib contrib-type="author"><name><surname>SATOMI</surname><given-names>FUKINO</given-names></name><xref ref-type="aff" rid="af1-etm-07-02-0456">1</xref></contrib><contrib contrib-type="author"><name><surname>SHIMA</surname><given-names>HIROAKI</given-names></name><xref ref-type="aff" rid="af1-etm-07-02-0456">1</xref></contrib><contrib contrib-type="author"><name><surname>OHNO</surname><given-names>KEISUKE</given-names></name><xref ref-type="aff" rid="af1-etm-07-02-0456">1</xref></contrib><contrib contrib-type="author"><name><surname>KAMESHIMA</surname><given-names>HIDEKAZU</given-names></name><xref ref-type="aff" rid="af1-etm-07-02-0456">1</xref></contrib><contrib contrib-type="author"><name><surname>SUZUKI</surname><given-names>YASUYO</given-names></name><xref ref-type="aff" rid="af1-etm-07-02-0456">1</xref></contrib><contrib contrib-type="author"><name><surname>OHMURA</surname><given-names>TOUSEI</given-names></name><xref ref-type="aff" rid="af1-etm-07-02-0456">1</xref></contrib><contrib contrib-type="author"><name><surname>TAKAMARU</surname><given-names>HIROYUKI</given-names></name><xref ref-type="aff" rid="af2-etm-07-02-0456">2</xref></contrib><contrib contrib-type="author"><name><surname>NOJIMA</surname><given-names>MASANORI</given-names></name><xref ref-type="aff" rid="af3-etm-07-02-0456">3</xref></contrib><contrib contrib-type="author"><name><surname>MORI</surname><given-names>MITSURU</given-names></name><xref ref-type="aff" rid="af3-etm-07-02-0456">3</xref></contrib><contrib contrib-type="author"><name><surname>HIRATA</surname><given-names>KOICHI</given-names></name><xref ref-type="aff" rid="af1-etm-07-02-0456">1</xref><xref ref-type="corresp" rid="c1-etm-07-02-0456"></xref></contrib></contrib-group><aff id="af1-etm-07-02-0456"><label>1</label>First Department of Surgery, Sapporo Medical University, Sapporo, Hokkaido 060-8543, Japan</aff><aff id="af2-etm-07-02-0456"><label>2</label>First Department of Internal Medicine, Sapporo Medical University, Sapporo, Hokkaido 060-8543, Japan</aff><aff id="af3-etm-07-02-0456"><label>3</label>Department of Public Health, Sapporo Medical University, Sapporo, Hokkaido 060-8556, Japan</aff><author-notes><corresp id="c1-etm-07-02-0456">Correspondence to: Professor Koichi Hirata, First Department of Surgery, Sapporo Medical University, South 1 West 16, Chuo-ku, Sapporo, Hokkaido 060-8543, Japan, E-mail: <email>fujikane@sapmed.ac.jp</email></corresp></author-notes><pub-date pub-type="ppub"><month>2</month><year>2014</year></pub-date><pub-date pub-type="epub"><day>11</day><month>12</month><year>2013</year></pub-date><pub-date pub-type="pmc-release"><day>11</day><month>12</month><year>2013</year></pub-date><pmc-comment> PMC Release delay is 0 months and 0 days and was based on the
<volume>7</volume><issue>2</issue><fpage>456</fpage><lpage>460</lpage><history><date date-type="received"><day>19</day><month>6</month><year>2013</year></date><date date-type="accepted"><day>21</day><month>10</month><year>2013</year></date></history><permissions><copyright-statement>Copyright © 2014, Spandidos Publications</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0"><license-p>This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.</license-p></license></permissions><abstract><p>For sentinel lymph node biopsy (SLNB), a combination of dye-guided and γ-probe-guided methods is the most commonly used technique. However, the number of institutes in which the γ-probe-guided method is able to be performed is limited, since special equipment is required for the method. In this study, SLNB with the dye-guided method alone was evaluated, and the clinicopathological characteristics were analyzed to identify any factors that were predictive of whether the follow-up axillary lymph node dissection (ALND) was able to be omitted. A total of 374 patients who underwent SLNB between 1999 and 2009 were studied. The SLN identification rate was analyzed, in addition to the false-positive and false-negative rates and the correlation between the clinicopathological characteristics and axillary lymph node metastases. The SLN was identified in 96.8% of cases, and, out of the patients who had SLN metastasis, 63.0% did not exhibit metastasis elsewhere. The sensitivity was 96.4% and the specificity was 100%. The false-negative rate was 3.6%. Univariate analyses revealed significant differences in the lymph vessel invasion (ly) status, nuclear grade (NG), maximum tumor size and the percentage of the area occupied by the tumor cells in the SLN (SLN occupation ratio) between the patients with and without non-SLN metastasis, indicating that these factors may be predictive of axillary lymph node metastasis. Multivariate analysis revealed that ly status was an independent risk factor for non-SLN metastasis. In conclusion, SLN with the dye-guided method alone provided a high detection rate. The study identified a predictive factor for axillary lymph node metastasis that may improve the patients’ quality of life.</p></abstract><kwd-group><kwd>axillary lymph node dissection</kwd><kwd>breast cancer</kwd><kwd>dye-guided method</kwd><kwd>sentinel lymph node biopsy</kwd><kwd>prediction of lymph node metastasis</kwd></kwd-group></article-meta></front><body><sec><title>Introduction</title><p>Axillary lymph node dissection (ALND) provides information for staging and prognosis that may be used to design a therapeutic strategy (<xref rid="b1-etm-07-02-0456" ref-type="bibr">1</xref>–<xref rid="b3-etm-07-02-0456" ref-type="bibr">3</xref>). As a result of this, a large number of patients with breast cancer in the past underwent routine ALND; however, in many of the patients, the cancer was revealed to be node-negative, and surgery unnecessarily exposed them to perioperative risks and increased long-term morbidity (<xref rid="b4-etm-07-02-0456" ref-type="bibr">4</xref>). Therefore, sentinel lymph node biopsy (SLNB) has widely replaced conventional ALND as a routine axillary staging method in breast cancer surgery. The SLNB procedure is accurate and safe (<xref rid="b5-etm-07-02-0456" ref-type="bibr">5</xref>–<xref rid="b8-etm-07-02-0456" ref-type="bibr">8</xref>) and results in substantially less postoperative morbidity than ALND (<xref rid="b9-etm-07-02-0456" ref-type="bibr">9</xref>,<xref rid="b10-etm-07-02-0456" ref-type="bibr">10</xref>).</p><p>Dye-guided and γ-probe-guided methods, separately and in combination, are used for SLNB. The dye-guided method alone for breast cancer is considered to be inferior to the γ-probe-guided and combined methods in terms of its accuracy and false-negative rate. Cox <italic>et al</italic>(<xref rid="b11-etm-07-02-0456" ref-type="bibr">11</xref>) revealed the identification rates for SLNB to be 80.3% for the dye-guided technique, 88.6% for the γ-probe-guided method and 96.7% for the combination, based on a large number of procedures performed in a single center. Kim <italic>et al</italic>(<xref rid="b12-etm-07-02-0456" ref-type="bibr">12</xref>) showed that the rates for successfully identifying the SLN were 83.1, 89.2 and 91.9%, for the dye-guided-alone, γ-probe-guided-alone and combination methods, respectively [with the combination method being significantly more efficacious (P=0.007)], while the false-negative rates were 10.9, 8.8 and 7.0%, respectively (P=0.047).</p><p>The dye-guided method has the significant advantages of being more convenient to perform, less costly and possible to conduct in any institute with no special facilities. Although it requires a certain training period, this method may be preferable for all clinicians if its accuracy is demonstrated to be comparable to that of the combination method. Morrow <italic>et al</italic>(<xref rid="b13-etm-07-02-0456" ref-type="bibr">13</xref>) reported that there were no significant differences between the procedures with regard to the identification rate, accuracy, time spent for identification and number of SLNs. In the present study, the success rate in identifying the SLN, the accuracy and the SLN occupation ratio using the dye-guided method alone were investigated. Furthermore, the possibility of obviating the requirement for ALND in SLNB-positive cases was explored.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><sec><title>Patients</title><p>From January 1999 to December 2009, 374 patients with primary breast cancer underwent SLNB using the dye-guided method alone followed by radical surgery at Sapporo Medical University Hospital (Sapporo, Japan). The medical records of these patients were analyzed retrospectively and their clinicopathological characteristics were evaluated. This study was approved by The Ethics Committee of Sapporo Medical University (Sapporo, Japan). Informed consent was obtained from all patients prior to enrollment.</p></sec><sec><title>Surgical procedure</title><p>Under general anesthesia, 2–4 ml blue dye (indigo carmine) was injected at two sites surrounding the primary tumor and areola. Approximately 5 min later, a blunt dissection was performed through the mastectomy incision or a separate axillary incision until a dye-stained lymphatic tract or node was identified.</p></sec><sec><title>Pathological assessment</title><p>The SLN was split into three to four sections and analyzed as frozen specimens during surgery. These specimens were fixed in 10% formalin, stained with hematoxylin and eosin (H&E) and then re-examined histologically following surgery. The SLN area and the area of tumor cells in the SLN were calculated by multiplying the longest diameter by the minor axis. The SLN occupation ratio was defined as the proportion of area that was occupied by tumor cells to the total SLN area. As a feasibility study, ALND was completed for cases of at least level I or II following SLN excision in the first 54 cases to undergo surgery.</p></sec><sec><title>Statistical analysis</title><p>Continuous variables (age, maximum tumor size and SLN occupation ratio), dichotomous variables (estrogen receptor, progesterone receptor and human epidermal growth factor receptor type 2 status) and categorical variables [lymph vessel invasion (ly) status, vessel invasion (v) status and nuclear grade (NG)] were analyzed in a univariate logistic regression model using either the t-test or the χ<sup>2</sup> test. All variables were subsequently analyzed in a multivariable regression model. A receiver operating characteristic (ROC) curve was drawn on the basis of the SLN occupation ratio, and the area under the curve (AUC) was calculated using SPSS version 11.5 statistical software (SPSS, Inc., Chicago, IL, USA). GraphPad Prism version 5.0.2 (GraphPad Software, La Jolla, CA, USA) was used for all analyses. P<0.05 was considered to indicate a statistically significant difference.</p></sec></sec><sec sec-type="results"><title>Results</title><p>The clinicopathological characteristics of the patients are shown in <xref rid="tI-etm-07-02-0456" ref-type="table">Table I</xref>. The SLN was successfully identified in 362 of the 374 patients (96.8%). The average number of resected lymph nodes was 1.9 (range, 1–10). A total of 54 patients were identified to have SLN metastases and ALND was performed in these patients. In 34 of the 54 patients (63.0%) with axillary metastases, metastatic nodes were only observed in the SLN. In the remaining 20 patients (37.0%), metastases were observed in the SLN and the non-SLNs. Of the 308 patients without SLN metastases in the frozen sections, 49 underwent ALND. Two of these 49 had positive axillary lymph nodes in the formalin-fixed sections. Among the 259 patients who did not undergo ALND, six had positive formalin-fixed sections (<xref rid="f1-etm-07-02-0456" ref-type="fig">Fig. 1</xref>).</p><sec><title>Postoperative diagnosis of SLN metastases</title><p>The sensitivity for the identification of a histologically positive node was 96.4% (54/56) (<xref rid="tII-etm-07-02-0456" ref-type="table">Table IIA</xref>), and the specificity was 100%. The accuracy of SLN biopsy for the detection of metastatic disease was 98.1% (101/103). The positive predictive value was 100% (54/54) and the negative predictive value (the correlation between the negative SLNs and the negative axillary nodes) was 95.9% (47/49), with a false-negative rate of 3.6% (2/56).</p></sec><sec><title>Intraoperative diagnosis of SLN metastases</title><p>In 362 patients, the intraoperative diagnosis was confirmed by the final histological examination (with formalin-fixed specimens). However, in eight patients (12.9%) there was a false-negative intraoperative diagnosis and a tumor was identified on a permanent section of either the SLN or the non-SLNs. As a result, a diagnostic accuracy of 97.8%, a sensitivity of 87.1% and a specificity of 100% were achieved with H&E staining of the frozen sections (<xref rid="tII-etm-07-02-0456" ref-type="table">Table IIB</xref>).</p></sec><sec><title>Clinicopathological factors correlated with non-SLN metastasis</title><p>In 63% of the SLN-positive cases for which ALND was performed, metastasis was limited to the SLN. This result suggested the possibility that the resection of SLNs only may be sufficient to treat in excess of half of the cases with positive SLNs. Therefore, the cases were analyzed to reveal which factors were likely to indicate the potential for omitting the following ALND.</p><p>To investigate which factors correlated with non-SLN metastasis, the clinicopathological characteristics of the patients who underwent ALND and had SLN and non-SLN metastases were compared with those who underwent ALND and just had SLN metastasis. Univariate analyses revealed significant differences in the ly status (P=0.0002), NG (P=0.0433), maximum tumor size (P=0.0317) and the SLN occupation rate (P=0.0017) between the two groups. The results of the analyses for various characteristics are summarized in <xref rid="tIII-etm-07-02-0456" ref-type="table">Table III</xref>.</p><p>Multivariate analysis revealed that ly status was an independent risk factor for non-SLN metastasis (<xref rid="tIV-etm-07-02-0456" ref-type="table">Table IV</xref>). An ROC curve was generated to assess the clinical utility of the SLN occupation ratio for the prediction of non-SLN metastasis (sensitivity, 70.0%; specificity, 61.8%; AUC, 0.736).</p></sec><sec><title>Axillary recurrences</title><p>In this study group, 5 out of the total 374 cases (1.3%) had an axillary recurrence. Out of all the patients, 259 patients received SLNB alone and 4/259 patients (1.5%) showed axillary recurrence. By contrast, patients who received ALND had no axillary recurrence. The SLN was not able to be detected in 12 cases, and axillary recurrence was observed in one of these cases.</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>In the present study, the SLN identification rate with the dye-guided method alone was 97%, which was comparable with previous studies (<xref rid="b11-etm-07-02-0456" ref-type="bibr">11</xref>,<xref rid="b12-etm-07-02-0456" ref-type="bibr">12</xref>). The population of patients who had SLN metastasis was also consistent with those of previous studies. These data indicated that the dye-guided method alone was sufficient to detect SLN metastasis. In addition, the dye-guided method requires no special equipment, so widespread application may be expected in any institute.</p><p>In SLN metastasis-positive cases, subsequent ALND is generally performed. However, in the group observed in the present study, 63% of the patients had no axillary metastasis. These results may indicate that in excess of half the patients receive unnecessary additional surgery. In the management of breast cancer, ALND may dam up the flow of lymph vessels and result in lymphedema in the patient’s arm. Although breast cancer is a malignant disease, survival may be relatively long subsequent to the first surgical therapy, so it is important to support the patient’s quality of life (QOL).</p><p>The possibility of predicting axillary lymph node metastasis by the analysis of the SLN status was investigated. The aim of identifying the factors that predict axillary metastasis was to contribute to avoiding unnecessary ALND. Univariate analysis revealed significant differences in ly status, NG, maximum tumor size and the SLN occupation ratio between patients with axillary metastasis and those with SLN metastasis only. In breast cancer, lymph node metastasis may spread through the lymph nodes stepwise, following the lymph vessel route. Thus, ly status, NG, tumor size and the SLN occupation ratio are associated with axillary metastasis, and the analysis of these factors is likely to enhance our capability to predict the patients with axillary lymph node metastasis.</p><p>The multivariate analysis of the clinicopathological factors, including those mentioned previously, revealed a correlation between axillary metastasis and ly status. However, since it is necessary to assess these factors in permanent formalin-fixed specimens, it is difficult to use them to decide on the surgical procedure during the surgery itself. Therefore, in the present study, the clinical usefulness of the SLN occupation ratio, which is able to be diagnosed during surgery, was investigated. It was demonstrated that the greater the degree of the area occupied by tumor cells, the more invasive the tumor was to lymph vessels, with greater proliferative ability, a larger number of malignant cells, a more metastatic character, and the longer the time after metastasis. Thus, this parameter was expected to be correlated with axillary metastasis. The ROC curve analysis showed sufficient sensitivity and specificity (70.0 and 61.8%, respectively) when the cut-off point for deciding whether it was necessary to perform ALND for patients who may not actually have axillary lymph node metastasis was 12.9%. Thus, a predictive factor for axillary lymph node metastasis in breast cancer was identified, which suggests that it may be possible to avoid unnecessary axillary lymph node resection, and thereby improve the patients’ QOL.</p></sec></body><back><ref-list><title>References</title><ref id="b1-etm-07-02-0456"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Senofsky</surname><given-names>GM</given-names></name><name><surname>Moffat</surname><given-names>FL</given-names><suffix>Jr</suffix></name><name><surname>Davis</surname><given-names>K</given-names></name><etal></etal></person-group><article-title>Total axillary lymphadenectomy in the management of breast cancer</article-title><source>Arch Surg</source><volume>126</volume><fpage>1336</fpage><lpage>1342</lpage><year>1991</year><pub-id pub-id-type="pmid">1747046</pub-id></element-citation></ref><ref id="b2-etm-07-02-0456"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fentiman</surname><given-names>IS</given-names></name><name><surname>Mansel</surname><given-names>RE</given-names></name></person-group><article-title>The axilla: not a no-go zone</article-title><source>Lancet</source><volume>337</volume><fpage>221</fpage><lpage>223</lpage><year>1991</year><pub-id pub-id-type="pmid">1670853</pub-id></element-citation></ref><ref id="b3-etm-07-02-0456"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noguchi</surname><given-names>M</given-names></name><name><surname>Miwa</surname><given-names>K</given-names></name><name><surname>Michigishi</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>The role of axillary lymph node dissection in breast cancer management</article-title><source>Breast Cancer</source><volume>4</volume><fpage>143</fpage><lpage>153</lpage><year>1997</year><pub-id pub-id-type="pmid">11091589</pub-id></element-citation></ref><ref id="b4-etm-07-02-0456"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kissin</surname><given-names>MW</given-names></name><name><surname>Querci della Rovere</surname><given-names>G</given-names></name><name><surname>Easton</surname><given-names>D</given-names></name><etal></etal></person-group><article-title>Risk of lymphoedema following the treatment of breast cancer</article-title><source>Br J Surg</source><volume>73</volume><fpage>580</fpage><lpage>584</lpage><year>1986</year><pub-id pub-id-type="pmid">3730795</pub-id></element-citation></ref><ref id="b5-etm-07-02-0456"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>C</given-names></name><name><surname>White</surname><given-names>L</given-names></name><name><surname>Allred</surname><given-names>N</given-names></name><etal></etal></person-group><article-title>Survival outcomes in node-negative breast cancer patients evaluated with complete axillary node dissection versus sentinel lymph node biopsy</article-title><source>Ann Surg Oncol</source><volume>13</volume><fpage>708</fpage><lpage>711</lpage><year>2006</year><pub-id pub-id-type="pmid">16538416</pub-id></element-citation></ref><ref id="b6-etm-07-02-0456"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuijt</surname><given-names>GP</given-names></name><name><surname>van de Poll-Franse</surname><given-names>LV</given-names></name><name><surname>Voogd</surname><given-names>AC</given-names></name><etal></etal></person-group><article-title>Survival after negative sentinel lymph node biopsy in breast cancer at least equivalent to after negative extensive axillary dissection</article-title><source>Eur J Surg Oncol</source><volume>33</volume><fpage>832</fpage><lpage>837</lpage><year>2007</year><pub-id pub-id-type="pmid">17197151</pub-id></element-citation></ref><ref id="b7-etm-07-02-0456"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langer</surname><given-names>I</given-names></name><name><surname>Guller</surname><given-names>U</given-names></name><name><surname>Hsu-Schmitz</surname><given-names>SF</given-names></name><etal></etal></person-group><article-title>Sentinel lymph node biopsy is associated with improved survival compared to level I & II axillary lymph node dissection in node negative breast cancer patients</article-title><source>Eur J Surg Oncol</source><volume>35</volume><fpage>805</fpage><lpage>813</lpage><year>2009</year><pub-id pub-id-type="pmid">19046846</pub-id></element-citation></ref><ref id="b8-etm-07-02-0456"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Ploeg</surname><given-names>IM</given-names></name><name><surname>Nieweg</surname><given-names>OE</given-names></name><name><surname>van Rijk</surname><given-names>MC</given-names></name><etal></etal></person-group><article-title>Axillary recurrence after a tumour-negative sentinel node biopsy in breast cancer patients: a systematic review and meta-analysis of the literature</article-title><source>Eur J Surg Oncol</source><volume>34</volume><fpage>1277</fpage><lpage>1284</lpage><year>2008</year><pub-id pub-id-type="pmid">18406100</pub-id></element-citation></ref><ref id="b9-etm-07-02-0456"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lucci</surname><given-names>A</given-names></name><name><surname>McCall</surname><given-names>LM</given-names></name><name><surname>Beitsch</surname><given-names>PD</given-names></name><etal></etal></person-group><article-title>Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011</article-title><source>J Clin Oncol</source><volume>25</volume><fpage>3657</fpage><lpage>3663</lpage><year>2007</year><pub-id pub-id-type="pmid">17485711</pub-id></element-citation></ref><ref id="b10-etm-07-02-0456"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Celebioglu</surname><given-names>F</given-names></name><name><surname>Perbeck</surname><given-names>L</given-names></name><name><surname>Frisell</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Lymph drainage studied by lymphoscintigraphy in the arms after sentinel node biopsy compared with axillary lymph node dissection following conservative breast cancer surgery</article-title><source>Acta Radiol</source><volume>48</volume><fpage>488</fpage><lpage>495</lpage><year>2007</year><pub-id pub-id-type="pmid">17520423</pub-id></element-citation></ref><ref id="b11-etm-07-02-0456"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>CE</given-names></name><name><surname>Bass</surname><given-names>SS</given-names></name><name><surname>McCann</surname><given-names>CR</given-names></name><etal></etal></person-group><article-title>Lymphatic mapping and sentinel lymph node biopsy in patients with breast cancer</article-title><source>Annu Rev Med</source><volume>51</volume><fpage>525</fpage><lpage>542</lpage><year>2000</year><pub-id pub-id-type="pmid">10774480</pub-id></element-citation></ref><ref id="b12-etm-07-02-0456"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>T</given-names></name><name><surname>Giuliano</surname><given-names>AE</given-names></name><name><surname>Lyman</surname><given-names>GH</given-names></name></person-group><article-title>Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis</article-title><source>Cancer</source><volume>106</volume><fpage>4</fpage><lpage>16</lpage><year>2006</year><pub-id pub-id-type="pmid">16329134</pub-id></element-citation></ref><ref id="b13-etm-07-02-0456"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morrow</surname><given-names>M</given-names></name><name><surname>Rademaker</surname><given-names>AW</given-names></name><name><surname>Bethke</surname><given-names>KP</given-names></name><etal></etal></person-group><article-title>Learning sentinel node biopsy: result of a prospective randomized trial of two techniques</article-title><source>Surgery</source><volume>126</volume><fpage>714</fpage><lpage>722</lpage><year>1999</year><pub-id pub-id-type="pmid">10520920</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-etm-07-02-0456" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Patient status. SLNB, sentinel lymph node biopsy; SLN, sentinel lymph node; ALND, axillary lymph node dissection.</p></caption><graphic xlink:href="ETM-07-02-0456-g00"></graphic></fig><table-wrap id="tI-etm-07-02-0456" orientation="portrait" position="float"><label>Table I</label><caption><p>Characteristics of 374 patients who underwent SLNB.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Clinical features</th><th align="center" valign="bottom" rowspan="1" colspan="1">No. of patients (%)</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Mean age, years (range)</td><td align="center" valign="top" rowspan="1" colspan="1">56.7 (23–87)</td></tr><tr><td colspan="2" align="left" valign="top" rowspan="1">Location of tumor</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Medial</td><td align="center" valign="top" rowspan="1" colspan="1">103 (27.5)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Lateral</td><td align="center" valign="top" rowspan="1" colspan="1">264 (70.6)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Central</td><td align="center" valign="top" rowspan="1" colspan="1">7 (1.9)</td></tr><tr><td colspan="2" align="left" valign="top" rowspan="1">Clinical tumor stage</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> T0</td><td align="center" valign="top" rowspan="1" colspan="1">14 (3.7)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> T1</td><td align="center" valign="top" rowspan="1" colspan="1">175 (46.8)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> T2</td><td align="center" valign="top" rowspan="1" colspan="1">161 (43.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> T3</td><td align="center" valign="top" rowspan="1" colspan="1">19 (5.1)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> T4</td><td align="center" valign="top" rowspan="1" colspan="1">5 (1.3)</td></tr><tr><td colspan="2" align="left" valign="top" rowspan="1">Clinical nodal stage</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> N0</td><td align="center" valign="top" rowspan="1" colspan="1">332 (88.8)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> N1</td><td align="center" valign="top" rowspan="1" colspan="1">41 (11.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> N2</td><td align="center" valign="top" rowspan="1" colspan="1">1 (0.3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> N3</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td colspan="2" align="left" valign="top" rowspan="1">No. of SLN</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> 1</td><td align="center" valign="top" rowspan="1" colspan="1">149 (39.8)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> 2</td><td align="center" valign="top" rowspan="1" colspan="1">130 (34.8)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> 3</td><td align="center" valign="top" rowspan="1" colspan="1">56 (15.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> 4</td><td align="center" valign="top" rowspan="1" colspan="1">18 (4.8)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> ≥5</td><td align="center" valign="top" rowspan="1" colspan="1">9 (2.4)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Not detected</td><td align="center" valign="top" rowspan="1" colspan="1">12 (3.2)</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-etm-07-02-0456"><p>SLNB, sentinel lymph node biopsy.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tII-etm-07-02-0456" orientation="portrait" position="float"><label>Table II</label><caption><p>Diagnosis of sentinel lymph node metastases.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="4" align="left" valign="bottom" rowspan="1">A. Postoperative diagnosis</th></tr><tr><th colspan="4" align="left" valign="bottom" rowspan="1"><hr></hr></th></tr><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Postoperative diagnosis</th><th align="center" valign="bottom" rowspan="1" colspan="1">SLN or non-SLN-positive</th><th align="center" valign="bottom" rowspan="1" colspan="1">SLN and non-SLN-negative</th><th align="center" valign="bottom" rowspan="1" colspan="1">Total</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">SLN-positive</td><td align="center" valign="top" rowspan="1" colspan="1">54</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="right" valign="top" rowspan="1" colspan="1">54</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SLN-negative</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">47</td><td align="right" valign="top" rowspan="1" colspan="1">49</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Total</td><td align="center" valign="top" rowspan="1" colspan="1">56</td><td align="center" valign="top" rowspan="1" colspan="1">47</td><td align="right" valign="top" rowspan="1" colspan="1">103</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1"><hr></hr></td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">B. Intraoperative diagnosis</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1"><hr></hr></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Intraoperative diagnosis</td><td align="center" valign="top" rowspan="1" colspan="1">SLN-positive</td><td align="center" valign="top" rowspan="1" colspan="1">SLN-negative</td><td align="right" valign="top" rowspan="1" colspan="1">Total</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1"><hr></hr></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SLN-positive</td><td align="center" valign="top" rowspan="1" colspan="1">54</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="right" valign="top" rowspan="1" colspan="1">54</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SLN-negative</td><td align="center" valign="top" rowspan="1" colspan="1">8</td><td align="center" valign="top" rowspan="1" colspan="1">300</td><td align="right" valign="top" rowspan="1" colspan="1">308</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Total</td><td align="center" valign="top" rowspan="1" colspan="1">62</td><td align="center" valign="top" rowspan="1" colspan="1">300</td><td align="right" valign="top" rowspan="1" colspan="1">362</td></tr></tbody></table><table-wrap-foot><fn id="tfn2-etm-07-02-0456"><p>Postoperative diagnosis: The sensitivity for sentinel lymph node (SLN) metastasis was 96.4%, the specificity was 100% and the false-negative rate was 3.6%. Intraoperative diagnosis: A diagnostic accuracy of 97.8%, a sensitivity of 87.1% and specificity of 100% were achieved with hematoxylin and eosin (H&E) staining in the frozen sections; the false-negative rate was 12.9%.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tIII-etm-07-02-0456" orientation="portrait" position="float"><label>Table III</label><caption><p>Clinicopathological factors correlated with non-SLN metastasis.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Clinical feature</th><th align="center" valign="bottom" rowspan="1" colspan="1">SLN only</th><th align="center" valign="bottom" rowspan="1" colspan="1">SLN and non-SLN</th><th align="center" valign="bottom" rowspan="1" colspan="1">P-value</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Mean age (years)</td><td align="center" valign="top" rowspan="1" colspan="1">59.76</td><td align="center" valign="top" rowspan="1" colspan="1">59.85</td><td align="center" valign="top" rowspan="1" colspan="1">0.9820</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Tumor size (cm)</td><td align="center" valign="top" rowspan="1" colspan="1">2.34</td><td align="center" valign="top" rowspan="1" colspan="1">2.92</td><td align="center" valign="top" rowspan="1" colspan="1">0.0317<xref rid="tfn4-etm-07-02-0456" ref-type="table-fn">a</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ly</td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1">0.0002<xref rid="tfn5-etm-07-02-0456" ref-type="table-fn">b</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> ly0</td><td align="center" valign="top" rowspan="1" colspan="1">12</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> ly1–3</td><td align="center" valign="top" rowspan="1" colspan="1">20</td><td align="center" valign="top" rowspan="1" colspan="1">20</td><td align="center" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">v</td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1">0.2346</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> v0</td><td align="center" valign="top" rowspan="1" colspan="1">29</td><td align="center" valign="top" rowspan="1" colspan="1">15</td><td align="center" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> v1</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">5</td><td align="center" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NG</td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1">0.0433<xref rid="tfn4-etm-07-02-0456" ref-type="table-fn">a</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> 1</td><td align="center" valign="top" rowspan="1" colspan="1">20</td><td align="center" valign="top" rowspan="1" colspan="1">6</td><td align="center" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> 2–3</td><td align="center" valign="top" rowspan="1" colspan="1">11</td><td align="center" valign="top" rowspan="1" colspan="1">12</td><td align="center" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Unknown</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ER status</td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1">0.7208</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Negative</td><td align="center" valign="top" rowspan="1" colspan="1">7</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Positive</td><td align="center" valign="top" rowspan="1" colspan="1">24</td><td align="center" valign="top" rowspan="1" colspan="1">17</td><td align="center" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Unknown</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1"></td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">PgR status</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Negative</td><td align="center" valign="top" rowspan="1" colspan="1">10</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">0.0949</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Positive</td><td align="center" valign="top" rowspan="1" colspan="1">21</td><td align="center" valign="top" rowspan="1" colspan="1">18</td><td align="center" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Unknown</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HER2 status</td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1">0.6958</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Negative</td><td align="center" valign="top" rowspan="1" colspan="1">27</td><td align="center" valign="top" rowspan="1" colspan="1">16</td><td align="center" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Positive</td><td align="center" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Unknown</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SLN occupation ratio (%)</td><td align="center" valign="top" rowspan="1" colspan="1">21.47</td><td align="center" valign="top" rowspan="1" colspan="1">46.75</td><td align="center" valign="top" rowspan="1" colspan="1">0.0017<xref rid="tfn5-etm-07-02-0456" ref-type="table-fn">b</xref></td></tr></tbody></table><table-wrap-foot><fn id="tfn3-etm-07-02-0456"><p>P-values were calculated using either the t-test or the χ<sup>2</sup> test.</p></fn><fn id="tfn4-etm-07-02-0456"><label>a</label><p>P<0.05,</p></fn><fn id="tfn5-etm-07-02-0456"><label>b</label><p>P<0.01.</p></fn><fn id="tfn6-etm-07-02-0456"><p>SLN, sentinal lymph node; ly, lymph vessel invasion; v, vessel invasion; NG, nuclear grade; ER, estrogen receptor; PgR, progesterone receptor; HER2, human epidermal growth factor type 2; SLN occupation ratio, percentage of SLN area occupied by tumor cells.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tIV-etm-07-02-0456" orientation="portrait" position="float"><label>Table IV</label><caption><p>Multivariate analysis.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Risk factor for SLN metastasis</th><th align="center" valign="bottom" rowspan="1" colspan="1">P-value</th><th align="center" valign="bottom" rowspan="1" colspan="1">Relative risk</th><th align="center" valign="bottom" rowspan="1" colspan="1">95% CI</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Age</td><td align="center" valign="top" rowspan="1" colspan="1">0.0938</td><td align="center" valign="top" rowspan="1" colspan="1">1.00</td><td align="center" valign="top" rowspan="1" colspan="1">0.93–1.07</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Maximum tumor size</td><td align="center" valign="top" rowspan="1" colspan="1">0.1477</td><td align="center" valign="top" rowspan="1" colspan="1">2.09</td><td align="center" valign="top" rowspan="1" colspan="1">0.81–8.24</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">ly</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> ly0</td><td align="center" valign="top" rowspan="1" colspan="1">0.0138<xref rid="tfn7-etm-07-02-0456" ref-type="table-fn">a</xref></td><td align="center" valign="top" rowspan="1" colspan="1">1.00</td><td align="center" valign="top" rowspan="1" colspan="1">1.95–5.14×10<sup>19</sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> ly1–3</td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1">7.08×10<sup>8</sup></td><td align="center" valign="top" rowspan="1" colspan="1"></td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">v</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> v0</td><td align="center" valign="top" rowspan="1" colspan="1">0.4950</td><td align="center" valign="top" rowspan="1" colspan="1">1.00</td><td align="center" valign="top" rowspan="1" colspan="1">0.27–20.47</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> v1</td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1">2.03</td><td align="center" valign="top" rowspan="1" colspan="1"></td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">NG</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> 1</td><td align="center" valign="top" rowspan="1" colspan="1">0.1258</td><td align="center" valign="top" rowspan="1" colspan="1">1.00</td><td align="center" valign="top" rowspan="1" colspan="1">0.68–29.32</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> 2–3</td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1">4.05</td><td align="center" valign="top" rowspan="1" colspan="1"></td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">ER status</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Negative</td><td align="center" valign="top" rowspan="1" colspan="1">0.8965</td><td align="center" valign="top" rowspan="1" colspan="1">1.00</td><td align="center" valign="top" rowspan="1" colspan="1">0.105–12.33</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Positive</td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1">1.16</td><td align="center" valign="top" rowspan="1" colspan="1"></td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">PgR status</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Negative</td><td align="center" valign="top" rowspan="1" colspan="1">0.0823</td><td align="center" valign="top" rowspan="1" colspan="1">1.00</td><td align="center" valign="top" rowspan="1" colspan="1">0.791–145.56</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Positive</td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1">7.30</td><td align="center" valign="top" rowspan="1" colspan="1"></td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">HER2 status</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Negative</td><td align="center" valign="top" rowspan="1" colspan="1">0.2760</td><td align="center" valign="top" rowspan="1" colspan="1">1.00</td><td align="center" valign="top" rowspan="1" colspan="1">0.43–25.07</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Positive</td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1">3.00</td><td align="center" valign="top" rowspan="1" colspan="1"></td></tr></tbody></table><table-wrap-foot><fn id="tfn7-etm-07-02-0456"><label>a</label><p>P<0.05.</p></fn><fn id="tfn8-etm-07-02-0456"><p>SLN, sentinel lymph node; CI, confidence interval; ly, lymph vessel invasion; v, vessel invasion; NG, nuclear grade; ER, estrogen receptor; PgR, progesteron receptor; HER2, human epidermal growth factor type 2.</p></fn></table-wrap-foot></table-wrap></floats-group></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003E38 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 003E38 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.31. |  |